Reading the annual reports…

First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.

BOSTON SCIENTIFIC CORP (BSX) financial health, profit and balance sheet · Scorvest

BSX · NYSE · United States · Surgical & Medical Instruments & Apparatus

BOSTON SCIENTIFIC CORP

Marlborough, MA · Fiscal year ends in December · Figures in USD

+ Add to watchlist Compare

In shortBOSTON SCIENTIFIC CORP is profitable, generates cash and carries moderate debt, with revenue growing (+19.9% last year).

Financial health

Strong

Built from five areas over the last five annual reports. Tap an area to see the figures behind it.

How is this score calculated? →

Profitability69

Operating marginShare of each sale left after running the business, before interest and tax.	18.0%	77/100
Net marginShare of each sale left as profit after every cost, interest and tax.	14.4%	78/100
Return on equityProfit earned on the money shareholders put in. Above 15% is strong.	12.6%	63/100
Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge.	8.7%	58/100

Weight in the score: 25%

Balance sheet68

Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash.	1.62×	68/100
Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted.	0.47×	85/100
Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable.	1.90×	60/100
Interest coverageHow many times operating profit covers interest. Below 2 is risky.	10.35×	84/100
Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress.	2.78	43/100

Weight in the score: 25%

Cash generation98

Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt.	18.2%	93/100
Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy.	1.26×	100/100
Years with positive free cash flow (last 5)	5 of 5	100/100

Weight in the score: 20%

Stability93
Profitable years (last 5) 5 of 5 100/100
Years of revenue decline (last 5) 0 of 5 100/100
Revenue growth volatility 5.7% 90/100
Operating margin volatility 3.1% 81/100
Weight in the score: 20%
Growth100
Revenue growth, 3-year average 16.5% 100/100
EPS growth, 3-year average 62.8% 100/100
Weight in the score: 10%

Profitable years (last 5)	5 of 5	100/100
Years of revenue decline (last 5)	0 of 5	100/100
Revenue growth volatility	5.7%	90/100
Operating margin volatility	3.1%	81/100

Revenue growth, 3-year average	16.5%	100/100
EPS growth, 3-year average	62.8%	100/100

Fiscal year 2025 · change vs prior year

Revenue: $20.1B; ▲ 19.9%
Net income: $2.9B; ▲ 56.4%
Free cash flow: $3.7B; ▲ 38.3%
Operating margin: 18.0%; +2.5 pts
Cash & investments: $2.0B; –
Total debt: $11.4B; ▲ 6.4%
Diluted EPS: $1.94; ▲ 55.2%
Return on equity: 12.6%; –

Trends

Annual figures as reported. Hover a bar or point for the exact value.

5 older years available with the 10-year history. Essential plan, from €8.25/month →

Revenue and net income

RevenueNet income

Margins

Statements

The last 5 fiscal years from the company's annual reports.

USD millions; negative values in parentheses.

Fiscal year	FY21	FY22	FY23	FY24	FY25
Revenue	11,888	12,682	14,240	16,747	20,074
Cost of revenue	3,711	3,956	4,345	5,257	6,221
Gross profit	8,177	8,727	9,896	11,490	13,854
Research & development	1,204	1,323	1,414	1,615	2,052
Selling, general & admin	4,359	4,520	5,190	5,984	6,887
Operating income	1,199	1,649	2,343	2,603	3,613
Interest expense	341	470	265	305	349
Pre-tax income	1,076	1,141	1,985	2,282	3,385
Income tax	36	443	393	436	493
Net income	985	642	1,570	1,853	2,898
Diluted EPS	$0.69	$0.45	$1.07	$1.25	$1.94
Diluted shares (millions)	1,434	1,440	1,464	1,486	1,495

5 older years available with the 10-year history. Essential plan, from €8.25/month →

Quarterly results

The last 8 reported quarters (10-Q and 10-K filings), in USD millions. The fourth quarter is derived from the annual report.

The last 8 quarters of BOSTON SCIENTIFIC CORP are included in the Investor plan. Try free for 7 days →

Risk checks

Altman Z'' score

2.78 Safe zone

Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.

Piotroski F-score

7/9

Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.

Positive net income: passed
Positive operating cash flow: passed
Return on assets improved: passed
Cash flow exceeds net income: passed
Long-term debt ratio fell: failed
Current ratio improved: passed
No share dilution: failed
Gross margin improved: passed
Asset turnover improved: passed

Sources

10-QPeriod ending Jun 30, 2026Filed Aug 3, 2026Open the report ↗
10-QPeriod ending Mar 31, 2026Filed May 1, 2026Open the report ↗
10-KPeriod ending Dec 31, 2025Filed Feb 17, 2026Open the report ↗
10-QPeriod ending Sep 30, 2025Filed Nov 3, 2025Open the report ↗
10-QPeriod ending Jun 30, 2025Filed Aug 1, 2025Open the report ↗
10-QPeriod ending Mar 31, 2025Filed May 1, 2025Open the report ↗
10-KPeriod ending Dec 31, 2024Filed Feb 18, 2025Open the report ↗
10-QPeriod ending Sep 30, 2024Filed Nov 1, 2024Open the report ↗